ICHOM and ICON. GLobal Outcomes BEnchmarking (GLOBE) TechConnect-Live Barbara Skerritt Director of Product Innovation, ICON.

Transcription

1 ICHOM and ICON GLobal Outcomes BEnchmarking (GLOBE) TechConnect-Live Barbara Skerritt Director of Product Innovation, ICON 30 th May 2018

2 ICHOM S FOUNDERS Michael E. Porter Board Member and Founder of ICHOM Michael E. Porter, PhD, is the Bishop William Lawrence University Professor at Harvard Business School. He is recognized as a global leader in strategy and competition, and brings more than two decades of experience developing the value framework, which is described in the book he co-authored with his colleague Professor Elizabeth O. Teisberg, PhD, Redefining Health Care Stefan Larsson Board Member and Founder of ICHOM Stefan Larsson, MD, PhD, is Senior Partner and Managing Director at The Boston Consulting Group, and is head of the firm s global health provider and payer sector. In addition, he is a group fellow at The Boston Consulting Group and leads the firm s research on the impact and implementation of value-based health care Martin Ingvar Board Member and Founder of ICHOM Martin Ingvar, MD, PhD, is a Professor in Neurophysiology and former Dean of Research at Karolinska Institutet. In addition, he is a Professor of Integrative Medicine at Osher Center for Integrative Medicine. His research focus is on pain and emotional regulation mechanisms in the brain

3 This is not a new concept Every hospital should follow every patient it treats long enough to determine whether or not the treatment has been successful, and then to inquire, if not, why not? with a view to preventing similar failures in the future - Ernest Codman (1914, Boston) Source: Donabedian. Milbank Quarterly

4 Value-based health care (VBHC) is gaining momentum around the world and will drive the next phase of health care reform Payers Pharma/Med Tech Health Provider Research Orgs Clinicians Patients Regulators Value = Outcome Cost A patient-centered approach to deliver better outcomes at the same or lower cost

5 ICHOM s Strategic Agenda ICHOM defines internationally recognized Standard Sets of outcomes and related case-mix factors ICHOM will provide riskadjusted international benchmarks on outcomes by medical condition ICHOM will become a methodological partner with media to publish ratings based on ICHOM outcomes Define Standards Measure outcomes Benchmark on outcomes 1 Collaborate to improve value 1 Establish outcomes transparency Develop value-based payment models VBHC ICHOM facilitates adoption and implementation by sharing knowledge and supporting proof-of-concept ICHOM will enable cooperation to improve value by establishing value collaboratives ICHOM will engage payers and governments to realign financial incentives and promote transparency Core mission of ICHOM Enabler role Current focus

6 ICHOM's global outcomes benchmarking program is exciting work that has never been done before ICHOM and ICON benchmarking outcomes across the globe ICHOM and ICON collected Cataract and Hip/Knee/Osteoarthritis Standard Set data from leading providers across the globe Countries Sites Patients (Since '16) Cataracts k Hip/Knee/ Osteoarthritis k Progress and Impact: Risk-adjustment of raw data and benchmark on key indicators focusing on patient-reported outcomes Individual reporting to participating organizations Best-in-class organizations identified with intent to publish about their performance

7 Objectives of the GLOBE pilots The GLOBE pilots aim to address two main questions: 1 2 Can we build it? Data governance and data flow: demonstrate feasibility of aggregating data across borders on a harmonized dataset Technological: demonstrate feasibility of data collection within an ecosystem of different collection solutions Is it a valuable service? Is there meaningful outcome variation in our data? Can we stimulate more rapid improvement informed by international outcomes data? The answers have helped us to understand whether it is feasible & valuable to scale this program

8 GLOBE Participants in HKO and CAT Pilots

9 Finalize program materials Month 1 Month 2 Month 3 Month 4 Onboard sites End of Month 4 Program Design Phase 4 months Conduct study plan review / governance call (group) Receive signed participation agreements from submitting sites Conduct technical calls (1:1) Receive first test data Finalize and distribute study plan Finalize and distribute key indicators and data transfer specifications

10 Data collection

11 Timeline and key figures of GLOBE Pilots End of Pilot ~18 months GLOBE Pilot Program Design (3/4 months) Data Collection (~12 months) Reporting (1/2 months) CAT Key Figures: HKO Key Figures : participating institutions (53 sites) 1 11 participating institutions (25 sites) 24 providing production data 2 15 sites providing production data 62,220 records of operative eyes 3 6,602 surgical records of hip and knee joints with osteoarthritis OVER 200 data transfers

12 ICHOM's analytics portal enables powerful insights

13 GLOBE program outcomes what have we learned? Provide the legal framework to facilitate data transfer Assess the data transfer mechanism that is acceptable for hospitals and scalable Detecting and understanding the variation between hospitals Development of risk adjustment tools and benchmarking analyses / visualizations Provides lessons learned for appropriate application, administration and effective use of patientreported outcomes (PROs) and PRO measurement (PROM) instruments Serves as a proof-of-concept for data management, analysis, and reporting processes required for international benchmarking More work required improve implementation and to ensure the integrity of the data Offers a foundation for a long-term benchmarking programs for other conditions

14 Outcomes data can help answer key questions for all stakeholders, from patients to entire health systems Direct clinical care Comparison & benchmarking Systems-level use of data How is our patient doing today? Communication through PROM measurement How can help the patient understand what to expect Predicted response curves for patients by subgroup How do we know when an intervention may be warranted? PROMs and other outcome measures to trigger intervention How can I make better decisions for my patient/for myself in the clinic? Clinical/ decision support based on expected response to interventions /thresholds for patient segments How can I measure what I achieve? Provider comparison against itself Where does my hospital stand? Benchmarking on outcomes How do I improve the quality of care at my institution? Sharing of 'best practices' How can I learn when my patients fall below an acceptable threshold? Real time monitoring of outcomes with triggers 9 How can I better design payment models? Reimbursement models on relative quality (outcomes) and cost 10 How can we design better studies? International data set for hypothesis generation and testing 11 How can we assess if current interventions are effective? Real-world endpoints and registry research trials to test efficacy 12 How do we determine acceptable quality of care & improve treatment guidelines? Outcomes based reg/accreditation and 13 evidence-based guidelines How can I segment and leverage subgroups of patients based on response? Discover new patient segments to inform new diagnostics & treatment pathways

15 Thank you iconplc.com 2017 ICON. All rights reserved. Internal use only.